Status:
WITHDRAWN
Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme
Lead Sponsor:
Millennium Pharmaceuticals, Inc.
Conditions:
Glioblastoma Multiforme
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This is a safety study of tandutinib in combination with temozolomide and bevacizumab after people have received radiation therapy and temozolomide treatment. This study will determine the maximum saf...
Eligibility Criteria
Inclusion
- Diagnosis of glioblastoma multiforme
- Received radiotherapy for glioblastoma multiforme
- Patients who have not had previous treatments for glioblastoma multiforme (except for surgery, radiation and temozolomide therapy)
- Females that are postmenopausal for at least 1 year prior to screening visit
- 18 years of age and older
Exclusion
- Other brain cancers that are not diagnosed as glioblastoma multiforme
- female patients who are lactating or are pregnant
- HIV positive and/or any other active infection requiring therapy
- Known hepatitis B or hepatitis C infection
- Diagnosed or treated any other cancer within 2 years before the first dose
- History of cardiovascular conditions and/or vascular disease
- Allergic to any component of bevacizumab
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2010
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00904852
Start Date
June 1 2009
End Date
June 1 2010
Last Update
May 20 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.